SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Tuesday said it has acquired
Fluent BioSciences, developer of an emerging and highly differentiated
single-cell technology.

'The addition of Fluent BioSciences to Illumina will provide significant and new
capabilities to our customers in a key growth area and advances our multiomics
growth strategy,' said Steven Barnard, chief technology officer of Illumina.
'Single-cell research opens doors to new areas of discovery, and Fluent's
innovative, accessible, and flexible single-cell method will accelerate our
ability to deliver full multiomics solutions for our customers.'

Fluent's single-cell analysis technology eliminates the need for complex,
expensive instrumentation and microfluidic consumables.

The acquisition closed on July 9, 2024, and has been funded with cash on hand.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX